Celikoglu Firuz, Celikoglu Seyhan I, York Amanda M, Goldberg Eugene P
Istanbul University, Cerrahpasa Medical Faculty and Florence Nightingale Hospital, Turkey.
Lung Cancer. 2006 Feb;51(2):225-36. doi: 10.1016/j.lungcan.2005.10.012. Epub 2005 Dec 15.
Patients presenting with inoperable non-small cell carcinoma of the lung associated with severe bronchial obstruction are at a high risk for developing post-obstructive pneumonia or respiratory failure. This often leads to death in weeks to months. Several studies suggest that initial use of debulking of obstructed airways by Nd-YAG laser photo resection or by cryotherapy lessens morbidity by reducing infections and respiratory insufficiencies. This can shorten hospitalization, improve the quality of life, and prolong survival. It has also been demonstrated that patients first treated for debulking and then by irradiation have better survival than similar patients treated with irradiation alone. Intratumoral (IT) injection of cytotoxic drugs (IT chemotherapy) has also been successfully used to debulk airways. The aim of the present work was to study the effectiveness, safety, and feasibility of initial debulking by IT chemotherapy with cisplatin combined with irradiation with a curative intent in the treatment of obstructive inoperable non-small cell lung cancer.
Twenty three patients were treated first by bronchoscopic IT injection of up to 40 mg cisplatin solution (4 mg/ml), administered weekly four times (on days: 1, 8, 15, 22) and then by irradiation.
At the end of a 3-week period of IT treatment, 11 of 23 patients showed an increase in airway lumen diameter of more than 50% (good response), 8 patients showed an improvement of 25-50% (partial response) and 4 patients showed an increase of less than 25% (small response). Overall, debulking by IT chemotherapy was considered clinically effective in 19 of 23 patients and only marginally effective in 4 patients. Statistical analysis indicated a statistically significant improvement in lumen diameter (P < 0.001) for all patients. The combination of IT chemotherapy and irradiation resulted in prolonged survival in the patients with good response (median survival 636 days) compared to patients with partial response (median survival 342 days). The four patients with only a small response had a median survival of 202 days.
Debulking by intratumoral injection of cisplatin was shown to be a safe, simple, and cost effective procedure. There were no severe side effects and complications. Initial debulking of obstructed airways by IT administration of cisplatin, followed by irradiation requires further studies in order to determine its effect on survival.
患有无法手术切除的非小细胞肺癌且伴有严重支气管阻塞的患者发生阻塞性肺炎或呼吸衰竭的风险很高。这通常会在数周至数月内导致死亡。多项研究表明,最初通过钕钇铝石榴石激光光切除或冷冻疗法对阻塞气道进行减瘤,可通过减少感染和呼吸功能不全来降低发病率。这可以缩短住院时间,提高生活质量,并延长生存期。也已证明,先接受减瘤治疗然后进行放疗的患者比仅接受放疗的类似患者生存期更长。瘤内(IT)注射细胞毒性药物(IT化疗)也已成功用于气道减瘤。本研究的目的是探讨顺铂IT化疗联合放疗进行初始减瘤治疗不可手术切除的阻塞性非小细胞肺癌的有效性、安全性和可行性。
23例患者首先通过支气管镜IT注射高达40mg顺铂溶液(4mg/ml),每周注射4次(第1、8、15、22天),然后进行放疗。
在3周的IT治疗结束时,23例患者中有11例气道腔直径增加超过50%(良好反应),8例患者改善25%-50%(部分反应),4例患者增加小于25%(微小反应)。总体而言,23例患者中有19例的IT化疗减瘤被认为临床有效,4例仅略有效果。统计分析表明所有患者的腔直径有统计学显著改善(P<0.001)。与部分反应患者(中位生存期342天)相比,IT化疗和放疗联合治疗使反应良好的患者生存期延长(中位生存期636天)。4例微小反应患者的中位生存期为202天。
瘤内注射顺铂减瘤是一种安全、简单且经济有效的方法。没有严重的副作用和并发症。顺铂IT给药对阻塞气道进行初始减瘤后再进行放疗,其对生存期的影响有待进一步研究确定。